Prescribing Patterns of Gabapentinoids in Chronic Pain Management: A Single Institution Retrospective Chart Review

Overview

Journal Psychopharmacol Bull

Specialty Pharmacology

Date 2025 Jan 2

PMID 39744414

Authors

Richard T Tran

Anand S Patil

Parker P Nguyen

Grace H Nguyen

Amad Qadeer

Grant H Chen

Ranganathan Govindaraj

Jamal Hasoon

Affiliations

Soon will be listed here.

Abstract

Gabapentin and pregabalin are widely used in the management of neuropathic pain though their prescribing patterns, effectiveness, and safety profiles remain topics of ongoing research. This retrospective chart review analyzed the prevalence of gabapentinoid use in a chronic pain clinic over a one-year period from May 1, 2023, to April 30, 2024. The study examined patient records from four pain management physicians, focusing on those prescribed gabapentin or pregabalin. Of the 2,395 patients reviewed, 478 (19.96%) were prescribed gabapentin, while 236 (9.85%) received pregabalin. Combined, 714 patients (29.81%) were managed with either medication, highlighting the significant role gabapentinoids play in chronic pain treatment. The study found that gabapentin was prescribed more frequently than pregabalin. Although both medications are effective for neuropathic pain, their use comes with notable side effects, including dizziness, somnolence, and, in some cases, an increased risk of suicidal ideation. This review underscores the importance of careful patient monitoring and individualized treatment approaches when prescribing gabapentinoids. Future research across multiple sites and further stratification of patient demographics would enhance understanding of gabapentinoid use in clinical practice.

References

Davari M, Amani B, Amani B, Khanijahani A, Akbarzadeh A, Shabestan R . Pregabalin and gabapentin in neuropathic pain management after spinal cord injury: a systematic review and meta-analysis. Korean J Pain. 2020; 33(1):3-12. PMC: 6944364. DOI: 10.3344/kjp.2020.33.1.3. View

Attal N, Lanteri-Minet M, Laurent B, Fermanian J, Bouhassira D . The specific disease burden of neuropathic pain: results of a French nationwide survey. Pain. 2011; 152(12):2836-2843. DOI: 10.1016/j.pain.2011.09.014. View

Costigan M, Scholz J, Woolf C . Neuropathic pain: a maladaptive response of the nervous system to damage. Annu Rev Neurosci. 2009; 32:1-32. PMC: 2768555. DOI: 10.1146/annurev.neuro.051508.135531. View

Taylor C, Angelotti T, Fauman E . Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res. 2006; 73(2):137-50. DOI: 10.1016/j.eplepsyres.2006.09.008. View

Kneib C, Sibbett S, Carrougher G, Muffley L, Gibran N, Mandell S . The Effects of Early Neuropathic Pain Control With Gabapentin on Long-Term Chronic Pain and Itch in Burn Patients. J Burn Care Res. 2019; 40(4):457-463. DOI: 10.1093/jbcr/irz036. View

Vickers-Smith R, Sun J, Charnigo R, Lofwall M, Walsh S, Havens J . Gabapentin drug misuse signals: A pharmacovigilance assessment using the FDA adverse event reporting system. Drug Alcohol Depend. 2019; 206:107709. PMC: 7762328. DOI: 10.1016/j.drugalcdep.2019.107709. View

Torrance N, Smith B, Bennett M, Lee A . The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey. J Pain. 2006; 7(4):281-9. DOI: 10.1016/j.jpain.2005.11.008. View

Toth C . Substitution of gabapentin therapy with pregabalin therapy in neuropathic pain due to peripheral neuropathy. Pain Med. 2010; 11(3):456-65. DOI: 10.1111/j.1526-4637.2009.00796.x. View

Moulin D, Boulanger A, Clark A, Clarke H, Dao T, Finley G . Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society. Pain Res Manag. 2014; 19(6):328-35. PMC: 4273712. DOI: 10.1155/2014/754693. View

10.

Robertson K, Marshman L, Plummer D, Downs E . Effect of Gabapentin vs Pregabalin on Pain Intensity in Adults With Chronic Sciatica: A Randomized Clinical Trial. JAMA Neurol. 2018; 76(1):28-34. PMC: 6439871. DOI: 10.1001/jamaneurol.2018.3077. View

11.

Zesiewicz T, Elble R, Louis E, Gronseth G, Ondo W, Dewey Jr R . Evidence-based guideline update: treatment of essential tremor: report of the Quality Standards subcommittee of the American Academy of Neurology. Neurology. 2011; 77(19):1752-5. PMC: 3208950. DOI: 10.1212/WNL.0b013e318236f0fd. View

12.

Nwankwo A, Koyyalagunta D, Huh B, DSouza R, Javed S . A comprehensive review of the typical and atypical side effects of gabapentin. Pain Pract. 2024; 24(8):1051-1058. DOI: 10.1111/papr.13400. View

13.

Gammoh O, Al-Smadi A, Shawagfeh M, Abadi T, Kasawneh J, Malkawi S . The Clinical Difference between Gabapentin and Pregabalin: Data from a Pilot Comparative Trial. Rev Recent Clin Trials. 2021; 16(3):279-287. DOI: 10.2174/1574887116666210201110507. View

14.

Meaadi J, Obara I, Eldabe S, Nazar H . The safety and efficacy of gabapentinoids in the management of neuropathic pain: a systematic review with meta-analysis of randomised controlled trials. Int J Clin Pharm. 2023; 45(3):556-565. PMC: 10250255. DOI: 10.1007/s11096-022-01528-y. View

15.

Cohen S, Hayek S, Semenov Y, Pasquina P, White R, Veizi E . Epidural steroid injections, conservative treatment, or combination treatment for cervical radicular pain: a multicenter, randomized, comparative-effectiveness study. Anesthesiology. 2014; 121(5):1045-55. DOI: 10.1097/ALN.0000000000000409. View

16.

Murphy R, McGuinness D, Hallahan B . Pregabalin-induced sexual disinhibition. Ir J Psychol Med. 2020; 37(1):55-58. DOI: 10.1017/ipm.2017.5. View

17.

Ahmed S, Bachu R, Kotapati P, Adnan M, Ahmed R, Farooq U . Use of Gabapentin in the Treatment of Substance Use and Psychiatric Disorders: A Systematic Review. Front Psychiatry. 2019; 10:228. PMC: 6514433. DOI: 10.3389/fpsyt.2019.00228. View

18.

Bidari A, Moazen-Zadeh E, Ghavidel-Parsa B, Rahmani S, Hosseini S, Hassankhani A . Comparing duloxetine and pregabalin for treatment of pain and depression in women with fibromyalgia: an open-label randomized clinical trial. Daru. 2019; 27(1):149-158. PMC: 6593027. DOI: 10.1007/s40199-019-00257-4. View

19.

Aurora R, Kristo D, Bista S, Rowley J, Zak R, Casey K . Update to the AASM Clinical Practice Guideline: "The treatment of restless legs syndrome and periodic limb movement disorder in adults-an update for 2012: practice parameters with an evidence-based systematic review and meta-analyses". Sleep. 2012; 35(8):1037. PMC: 3397810. DOI: 10.5665/sleep.1986. View

20.

Leung J, Hall-Flavin D, Nelson S, Schmidt K, Schak K . The role of gabapentin in the management of alcohol withdrawal and dependence. Ann Pharmacother. 2015; 49(8):897-906. DOI: 10.1177/1060028015585849. View